Study start date
Participant must be ≥18 years of age inclusive, at the time of signing the informed consent.
Participants with following histologically or cytologically confirmed advanced solid tumors that have progressed after treatment with all available therapies for metastatic disease that are known to confer clinically meaningful benefit, or are intolerant to treatment, or refuse standard treatment.
Dose Escalation: all solid tumor types
Tumor type-specific Expansion cohorts:
NSCLCHNSCC with primary location in oropharynx, oral cavity, hypopharynx or larynx Urothelial Cancer Participants must have progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies. Have measurable disease per RECIST 1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Severe (Common terminology criteria for adverse events (CTCAE) v.5 Grade ≥ 3) infections within 4 weeks before the first study intervention administrationActive autoimmune disease that has required systemic treatment in past 2 years Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy Has active Central nervous system (CNS) metastases and/or carcinomatous meningitis. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. Cardiac disease as specified in the protocol